Acneiform reaction as an adverse effect of apremilast

Authors

  • Angélica Trujillo Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.
  • Mara Flamini Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.
  • Pamela Díaz Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.
  • Sandra García Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.
  • ítalo Aloise Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

DOI:

https://doi.org/10.47196/da.v25i1.2197

Keywords:

acneiform eruption, psoriasis, apremilast

Abstract

Apremilast is a phosphodiesterase-4 inhibitor that modulates the intracellular expression of cytokines, which are involved in the pathogenesis of psoriasis. Apremilast is indicated in moderate to severe plaque psoriasis, and it has shown good clinical results. The main adverse effects occur at a gastrointestinal level, and in less than 2% at the dermatologic level with exanthema and folliculitis. We present a 42-year-old patient that developed facial lesions after taking apremilast. The facial lesions were clinically and histopathologically correspond to an acneiform eruption. The patient evolved favorably and fully recovered after suspending apremilast.

Author Biographies

Angélica Trujillo, Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

Resident Physician.

Mara Flamini, Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

Former Chief of Residents.

Pamela Díaz, Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

Dermatologist Physician, Psoriasis Sector.

Sandra García, Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

Dermatopathologist.

ítalo Aloise, Dermatology Service, “Dr. Federico Abete” Trauma and Emergency Hospital, Malvinas Argentinas, Province of Buenos Aires.

Head of Service.

References

I. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83:1583-1590.

II. Papp K, Reich K, Leonardi CL, Kircik L, et ál. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015;73:37-49.

III. Informe de Posicionamiento Terapéutico de apremilast (Otezla®) en psoriasis cutánea y artritis psoriásica. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). 2015 pdf [Internet]. Disponible en: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-apremilast-Otezla.pdf. [Consultado junio 2020].

IV. Del Rosso JQ, Kircik L. Oral Apremilast for the Treatment of Plaque Psoriasis. J Clin Aesthet Dermatol 2016;9:43‐48.

V. Sobell JM, Foley P, Toth D, Mrowietz U, et ál. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol 2016;96:514-520.

VI. Highlights of prescribing information otezla_pi_english.pdf 2020 [Internet]. Disponible en: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/otezla/otezla_pi_english.ashx [Consultado junio 2020].

VII. Langley A, Beecker J. Management of common side effects of apremilast. J Cutan Med Surg 2018;22:415-421.

VIII. Tello E, Suaréz J, Beltrán E, Maldonado C, et ál. Manejo de los efectos adversos de apremilast desde un abordaje multidisciplinar. Actas Dermosifiliogr 2021;112:134-141.

IX. Paradela S, Fernández-Torres R, Martínez-Gómez W, Fonseca E. Apremilast en dermatología. Piel 2016;31:206-215.

X. Kazandjieva J, Tsankov N. Drug-induced acne. Clin Dermatol 2017;35:156-162.

Downloads

Published

2021-03-30

Issue

Vol. 27 No. 1 (2021): January-March 2021

Section

Clinical Cases

License

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor